#Amgen

[dustedmagazine]

Various Artists — Creiriau Y Delyn Rawn / Relics of the Horsehair Harp (Amgen)

Imagining new music is nothing new. Individually or collectively, spontaneously or through painstaking craft, research, and development, legions of music-makers have tried to come up with something sufficiently novel out of sounds and (sometimes) words that it hooks listeners’ attention. You can be sure that someone’s at it right now. But you probably won’t lose the farm if you bet it on the notion that the sequential imagining that went into the conception and execution of Creiriau Y Delyn Rawn is an unprecedented process that has yielded a remarkable outcome.

The Welsh language title translates into English as Relics Of The Horsehair Harp. It was produced by harpist Rhodri Davies as a companion to Telyn Rawn, a solo album that he released on his Amgen label. Telyn Rawn is named after the instrument that it introduced, a horsehair harp that Davies commissioned to be made by a couple harp makers and a leatherworker. Harps have a particular cultural resonance in Wales, since despite the instrument’s popularity, the art of making them nearly died out before making a comeback as part of a larger resurgence of Welsh culture. The original telyn rawn was made from wood and equine byproducts. After the sturdier Italian triple harp made it to the British Isles in the 1600s, it replaced the telyn rawn so thoroughly that for a couple centuries the triple harp was actually known as the Welsh harp (it was replaced by the pedal harp in the 20th century) while its predecessor was practically forgotten. When Davies, whose wide-ranging music encompasses free improvisation, modern composition, Konono-inspired junkyard noise, and rock and roll, got curious about those early harps, no one knew how to make one. The instrument on Telyn Rawn was designed using descriptions in early Welsh poetry and a couple pages addressing harp-tuning practices in a 17th century manuscript by Robert ap Huw.

When Davies finally set about playing the thing, he did not revive antique repertoire; he improvised short pieces equally informed both by his research and his own practice of playing freely, alone and with musicians like John Butcher, Andrew Leslie Hooker and the trio IST. Intricately plucked or vigorously bowed, some of the album’s eighteen tracks hinted at folkloric models, while others undid dense knots of sound that burst with harmonics and radiated overtones. Telyn Rawn came out during that first COVID summer, which was bad for many things, but was not so bad for spending some of that time that one wasn’t gigging cooking up new ideas. After its release, Davies reached out to friends and associates with this request: “I asked each contributor to imagine that the musical material improvised in 2020 was an ancient musical form that had fully existed in the medieval period, and that each of their responses were to have happened centuries after the imagined formation of the Telyn Rawn pieces.”

Such a brief can be taken in many directions, depending on the respondent’s experiences, equipment, and willingness to dig a new network out of someone else’s wormhole. Sixteen participants gave a response to one or two specific tracks from Telyn Rawn. Laura Cannell’s  opening piece, “The Tattered Skies Above,”  wastes little effort on interpreting Davies’ “Penriwh.” Instead, she constructs a fanfare from overdubbed recorders whose jolting sonorities and processional air establishes a through line linking a span of fantasized centuries. Next up, Orphy Robinson makes like a free-bopping jazz man. On “Nude, Lewd, Rude, Mood Food” he transfers bits of Davies’ intricate “Gorchan Sali” to a salaciously bulbous-sounding marimba, accelerates the tempo and lets it rip. Jem Finer plays “Y Geseg Fedi” pretty faithfully, simply transposing bowed harp to hurdy-gurdy; guitarist C. Joynes is similarly respectful to “”Dygan tro’r Ebill.” Credited as playing computer and mouse, “C. Spencer Yeh” visits a cut-and-splice surgical strike upon Davies’ recording of “Afon “Dewi Fawr;” Pat Thomas might do something similar on the turbulent electronic eruption, “Maddad.”

Not only does Davies have a strong musical personality that transcends the particular harp he plays and the century his head’s in; he has picked his emissaries wisely. Despite the disparity of instrumentation and approach exhibited by the sixteen contributing musicians, Creiriau Y Delyn Rawn feels pretty cohesive as it carves out an imaginary timeline of musical evolution.

Bill Meyer

[marklakshmanan]

https://www.medpagetoday.com/meetingcoverage/ada/116194?xid=nl_mpt_morningbreak2025-06-24&mh=04b3fab0856809eb8d5b4eee8e5ed787&zdee=gAAAAABm4vbh613aknD-ZiAqg-dNwwghuyj6DR2QMHH-Rfh8t-RWx7r0ZDVK29f8wQZXfUsq-6EAjjP6ux-f_mG4G-2QQsGPta21WayO65bX-HvmO2KePfk%3D&utm_source=Sailthru&utm_medium=email&utm_campaign=MorningBreak_062425&utm_term=NL_Gen_Int_Daily_News_Update_active

Interesting phase II data.

[jtrav]

Backpedal lead to a bone break? 💔

Just wrapped a photo campaign highlighting the hidden risks of osteoporosis, showing how everyday actions can lead to serious fractures. Working with a talented creative and medical team, we created cinematic scenes to convey the fragility of life post-menopause, focusing on empathy, realism, and impact. A big thank you to the team for bringing this vision to life through purposeful visual storytelling. Produced by Jellybean Partners BoneBreakingPoint.com Los Angeles, CA / February 2025

[newstech24]

Amgen Inventory: Imdelltra Knowledge And Q1 Outcomes Impress (NASDAQ:AMGN)

This text was written by Comply with With over twenty years of devoted expertise in funding, Allka Analysis has been a guiding drive for people looking for profitable alternatives. Its conservative strategy units it aside, persistently unearthing undervalued property throughout the realms of ETFs, commodities, know-how, and pharmaceutical corporations.Allka Analysis’s journey within the funding…

[newsepick]

Frailty linked to diminished quality of life in cancer and transplant survivors

A research paper published in *Aging* examines the prevalence of frailty in breast cancer and hematopoietic cell transplant survivors, highlighting its correlation with long-term diminished physical performance and quality of life. Conducted by researchers from the University of Minnesota, Columbia University, and Amgen, the study reveals a significant association between frailty and the aging biomarker p16INK4a. The findings emphasize the urgent need for targeted interventions, including senolytic trials, to address frailty and improve the overall wellbeing of these survivor populations

[widows-and-orphans-united]

Bringing Light to the Shadows: A Journey with Widows and Orphans

We believe in the power of collective action to bring light into the shadows of our society. By joining hands, we can create a world where the cries for help are heard and answered with love, care, and support.

Bringing Light to the Shadows: A Journey with Widows and Orphans In the United States, over 400,000 children are living in foster care, a system grappling with limited resources and fluctuating support. Simultaneously, an estimated 12 million elderly Americans live alone, facing challenges of isolation, health care, and financial insecurity. These statistics highlight a stark reality: our…

[crweworld]

(via Biopharmaceutical Giant Amgen to Settle FTC and State Challenges to its Horizon Therapeutics Acquisition)

[whereserpentswalk]

Your body will transform to fit the world you go to, and you can choose for time to pass slower on your original world. There's a good chance you'll end up dating (and probably fucking) the creature you with if that's the thing you're into. You can still contact them after you go back home.

Reblog to get them to appear swiftly. Like to give them a little treat on their way there.

[10bmnews]

These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says

Investors are underappreciating the effect generative artificial intelligence will have on biotech stocks, according to Jefferies. Biotech stocks have had a challenging couple of years, falling into a correction after an initial surge at the onset of the Covid-19 pandemic, as they navigated a higher interest rate environment. More recently, tariffs and staffing reductions at the U.S. Department…

[reasonsforhope]

"The Biden administration on Thursday [August 15, 2024] released prices for the first 10 prescription drugs that were subject to landmark negotiations between drugmakers and Medicare, a milestone in a controversial process that aims to make costly medications more affordable for older Americans. 

The government estimates that the new negotiated prices for the medications will lead to around $6 billion in net savings for the Medicare program in 2026 alone when they officially go into effect, or 22% net savings overall. That is based on the estimated savings the prices would have produced if they were in effect in 2023, senior administration officials told reporters Wednesday.

The Biden administration also expects the new prices to save Medicare enrollees $1.5 billion in out-of-pocket costs in 2026 alone.

“For so many people, being able to afford these drugs will mean the difference between debilitating illness and living full lives,” Chiquita Brooks-LaSure, administrator for the Centers for Medicare & Medicaid Services, told reporters. “These negotiated prices. They’re not just about costs. They are about helping to make sure that your father, your grandfather or you can live longer, healthier.”

It comes one day before the second anniversary of President Joe Biden’s signature Inflation Reduction Act, which gave Medicare the power to directly hash out drug prices with manufacturers for the first time in the federal program’s nearly 60-year history.

Here are the negotiated prices for a 30-day supply of the 10 drugs, along with their list prices based on 2023 prescription fills, according to a Biden administration fact sheet Thursday.

What Medicare and beneficiaries pay for a drug is often much less than the list price, which is what a wholesaler, distributor or other direct purchaser paid a manufacturer for a medication before any discounts...

The administration unveiled the first set of medications selected for the price talks in August 2023, kicking off a nearly yearlong negotiation period that ended at the beginning of the month.

The final prices give drugmakers, which fiercely oppose the policy, a glimpse of how much revenue they could expect to lose over the next few years. It also sets a precedent for the additional rounds of Medicare drug price negotiations, which will kick off in 2025 and beyond. 

First 10 drugs subject to Medicare price negotiations

Eliquis, made by Bristol Myers Squibb, is used to prevent blood clotting to reduce the risk of stroke. 

Jardiance, made by Boehringer Ingelheim and Eli Lilly, is used to lower blood sugar for people with Type 2 diabetes. 

Xarelto, made by Johnson & Johnson, is used to prevent blood clotting, to reduce the risk of stroke.

Januvia, made by Merck, is used to lower blood sugar for people with Type 2 diabetes.

Farxiga, made by AstraZeneca, is used to treat Type 2 diabetes, heart failure and chronic kidney disease. 

Entresto, made by Novartis, is used to treat certain types of heart failure.

Enbrel, made by Amgen, is used to treat autoimmune diseases such as rheumatoid arthritis. 

Imbruvica, made by AbbVie and J&J, is used to treat different types of blood cancers. 

Stelara, made by Janssen, is used to treat autoimmune diseases such as Crohn’s disease.

Fiasp and NovoLog, insulins made by Novo Nordisk.

In a statement Thursday, Biden called the new negotiated prices a “historic milestone” made possible because of the Inflation Reduction Act. He specifically touted Vice President Kamala Harris’ tiebreaking vote for the law in the Senate in 2022.

Harris, the Democratic presidential nominee, said in a statement that she was proud to cast that deciding vote, adding there is more work to be done to lower health-care costs for Americans.

“Today’s announcement will be lifechanging for so many of our loved ones across the nation, and we are not stopping here,” Harris said in a statement Thursday, noting that additional prescription drugs will be selected for future rounds of negotiations."

-via CNBC, August 15, 2024

[follow-up-news]

The Biden administration said Thursday that it had reached an agreement with drugmakers to lower prices on the 10 costliest prescription drugs under Medicare. It's part of the federal government's first-ever drug pricing negotiations, a cost reduction it claims could help ease the financial burden on the estimated 1 in 7 older adults in the U.S. struggling to pay for their medications. Here are the negotiated prices for the drugs, based on a 30-day supply: Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer: $231 negotiated price, down from $521 list price. Xarelto, a blood thinner from Johnson & Johnson; $197 negotiated price, down from $517 list price. Januvia, a diabetes drug from Merck: $113 negotiated price, down from $527 list price. Jardiance, a diabetes drug from Boehringer Ingelheim and Eli Lilly: $197 negotiated price, down from $573 list price. Enbrel, a rheumatoid arthritis drug from Amgen: $2,355 negotiated price, down from $7,106 list price. Imbruvica, a drug for blood cancers from AbbVie and Johnson & Johnson: $9,319 negotiated price, down from $14,934 list price. Farxiga, a drug for diabetes, heart failure and chronic kidney disease from AstraZeneca: $178 negotiated price, down from $556 list price. Entresto, a heart failure drug from Novartis: $295 negotiated price, down from $628 list price. Stelara, a drug for psoriasis and Crohn’s disease from J&J: $4,695 negotiated price, down from $13,836 list price. Fiasp and NovoLog, diabetes drugs from Novo Nordisk: $119 negotiated price, down from $495 list price.

[jtrav]

That's a Breaking Point 🩻💔

Just wrapped a photo campaign highlighting the hidden risks of osteoporosis, showing how everyday actions can lead to serious fractures. Working with a talented creative and medical team, we created cinematic scenes to convey the fragility of life post-menopause, focusing on empathy, realism, and impact. A big thank you to the team for bringing this vision to life through purposeful visual storytelling. Produced by Jellybean Partners BoneBreakingPoint.com Los Angeles, CA / February 2025

[gratisdiamanten]

NO SHORTCUTS TO HEAVEN:

Or, Lance Armstrong buys himself a gun.

No Shortcuts to Heaven, Billy Graham, Decision Magazine (2005). // Lance Armstrong is treated for testicular cancer, Linda Armstrong Kelly (1996). // Psalm 138:6 ESV. // Stalker, Andrei Tarkovsky (1979). // Lance Armstrong crashes out of Stage 5 of the Amgen Tour of California, Associated Press (2010). // Recycling Religion: Lance Armstrong’s Postmodern Spirituality of Suffering and Survivorship, William J. F. Keenan (2014). // Lance Armstrong is treated for testicular cancer, Linda Armstrong Kelley (1996). // Lance Armstrong during the 91st edition of the Tour de France, Tim de Waele (2004). // Recycling Religion: Lance Armstrong’s Postmodern Spirituality of Suffering and Survivorship, William J. F. Keenan (2014). // For Stacy (photo and excerpt), Lance Armstrong, Recovox News (2010). // It's Not About the Bike, Lance Armstrong (1999). // Lance Armstrong in a youth BMX race ca. 1982, Linda Armstrong Kelly, Sports Illustrated (2013). // Lance Armstrong: It Wasn’t Legal but I Wouldn’t Change a Thing, Reuters (2019). // Lance Armstrong getting a medical check up before the Tour de France, Franck Fife (2003). // Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial, Jules A. A. C. Heuberger et al., The Lancet (2017). // Crime and Punishment, Fyodor Dostoevsky (1866). // Luke 9:25 ESV. // Lance Armstrong at a victory procession for the Tour de France, Peter de Jong (2005). // Lance Armstrong climbing Alpe d'Huez, John Allen (2000). // It's Not About the Bike, Lance Armstrong (1999).

[nikethestatue]

Hello!

Wanted to get your thoughts on Elain not fitting into Night Court because per Cassian she is drowned out by “Night Court Black”? This also came up when Elain did not wear Illyrian leathers. One of the podcasts that I listen to (though mind you are very much in love with the red haired characters of the books, though they try to keep is unbiased) mentioned this. To me this has always been a bit of a faulty argument, especially about the Illyrian leathers because of course she would not want to wear that. Nesta was the same way. Cassian thinking that was an interesting way to word it—Mor nor Amgen regularly wear black yet he points this specifically out about Night Court. People tend to think well that must be it..Elain belongs in Day or Spring. Personally, I think SJM is perhaps pointing her to a different court all together—>Dusk perhaps???? Or it means absolutely nothing and Cassian is just oblivious to everyone except Nesta, despite the podcasters constantly talking about his emotional intelligence.

The 'black dress' comment has been addressed many times, and I can go back and kind of regurgitate the same info:

it's not the Night Court, it's specifically Hewn City

the plain black dress was there for a reason. To take all attention from her, and place it all on Nesta.

Elain volunteered HERSELF to go to Hewn City and play this role. She stated that she was 'part of this court' and would do what's necessary.

This is all canon and all in the book. So like I said, I am not going to regurgitate this info because the rebuttal of their arguments is already in there.

However, the Illyrian leathers thing is interesting.

Feyre stated that Elain possessed a 'different kind of strength' and SJM, in one of her interviews, said the same. Elain's strength, her powers are not connected to her abilities as a fighter. That's why she won't become a warrior. She is not a Blade. She is a loaf of bread. She is a flower. She is a rose in a mud field. She is a slice of cake. She is home. She is life. She is love. Her strength is that she does what is necessary, even if it's violent and cruel, and then she walks away. She doesn't dwell on it and doesn't take pride in causing pain.

However, unlike all of them, ELain was the only one who didn't need Illyrian leathers to deliver the most devastating blow of all--she stabbed the king. She didn't need any physical power to make a huge difference in the war--first by Seeing Vassa, who came in and destroyed the navy, and then by finding the Suriel with her Seer's Eyes, and through the Suriel, Amren learned how to shed her 'skin' and how to come to full power, thus developing a devastating blow to Hybern.

Elain has never been and hopefully will not be about fighting, slicing and dicing. Elain fully lives into the Nephelle philosophy. The weakest, the most 'insignificant' person can make the most difference. Nephelle with her too small wings, with her lack of physical powers also made a tremendous amount of difference in the previous War.

Cassian, the great warrior, the general, all clad in Illyrian leathers was no match for the King of Hybern. No matter his training, his physicality, his strength, he still fell, and was ready to die. But then Elain stepped out of the shadow and rammed Truth Teller through the King's throat.

That's her power. That's her strength. She does what needs to be done and then she returns to her quiet life, and continues to create.

That's the significance of Elain Archeron.

[covid-safer-hotties]

Also preserved on our archive

Summary: A new trial reveals that weekly injections of the weight-loss drug Wegovy (semaglutide) lowered the risk of death from COVID-19 by about a third and reduced overall mortality by 19%.

The study followed more than 17,000 participants with heart disease and obesity, showing that Wegovy decreased the likelihood of death from cardiovascular disease by 15% and other causes by 23%.

The findings are surprising, as the drug also lessened COVID-19 severity despite equal infection rates in both the Wegovy and placebo groups. Further studies are needed to understand the mechanisms behind these benefits.

Key Facts:

Wegovy reduced the risk of death from COVID-19 by 33% in trial participants. Overall mortality decreased by 19% for those on Wegovy compared to placebo. The study followed over 17,000 participants with heart disease and obesity. Source: Harvard

A trial study has found that injections of the weight-loss drug Wegovy reduced the risk of deaths from COVID-19 by about a third while also significantly reducing risk of death from cardiovascular disease or any other cause.

The trial was led by Harvard-affiliated Brigham and Women’s Hospital. It was funded by Novo Nordisk, makers of Wegovy (the brand name of semaglutide).

From October 2018 through March 2023, researchers studied the effect of once-weekly Wegovy shots versus placebo on mortality in more than 17,000 participants with heart disease and overweight or obesity.

The study showed that patients on Wegovy were about 15 percent less likely to die from cardiovascular disease and 23 percent less likely from other reasons as compared to those who took a placebo.

Overall death rates in the group taking Wegovy were 19 percent lower compared to placebo.

“The trial started before COVID-19, and we never anticipated a global respiratory pandemic,” said corresponding author Benjamin M. Scirica, director of quality initiatives at BWH’s Cardiovascular Division and professor of medicine at Harvard Medical School.

“It is rare for a cardio-metabolic drug to modify non-cardiovascular outcomes,” Scirica added.

“The fact that semaglutide reduced non-cardiovascular death, and in particular COVID-19-related deaths, was surprising. It opens up new avenues for exploring how this class of drugs may benefit patients.”

In the study, people taking Wegovy were just as likely to get COVID-19, but they had fewer serious illnesses or deaths related to COVID-19.

The researchers do not know if the benefit of Wegovy is due to weight loss or other effects, but suggest that extra weight may be the greatest contributor to lower life expectancy.

This result is from just one observation, albeit in a large, multinational study, so the findings need to be replicated. Further studies will explore potential mechanisms of action, and other studies of drugs in this class should provide additional data.

Disclosures: Benjamin Scirica reports institutional research grants to Brigham and Women’s Hospital from Better Therapeutics, Merck, Novo Nordisk, and Pfizer; consulting fees from Allergan, Amgen, Boehringer Ingelheim, Better Therapeutics, Elsevier Practice Update Cardiology, Esperion, Hanmi, Lexicon, and Novo Nordisk; and equity in health [at] Scale, and Doximity.

Funding: Novo Nordisk funded this study and was responsible for the study design in collaboration with the academic steering committee. They contributed to data collection, analysis, and interpretation and participated in the preparation and review of the manuscript in collaboration with the authors.

Study Link: www.jacc.org/doi/10.1016/j.jacc.2024.08.007

[widows-and-orphans-united]

Seizing the Fleeting Moments: How Chance Encounters Can Change the World

we’ve seen the magic that can happen when people from different walks of life come together.

Seizing the Fleeting Moments: How Chance Encounters Can Change the World In the relentless rush of life, I often forget to pause and appreciate the myriad of opportunities fluttering around like leaves in the wind. In these moments, these chance encounters, the potential for monumental change lies dormant, waiting to be awakened. I understand the immense power of these fleeting interactions and…